Post hoc analysis of 247 placebo-arm adults with Huntington disease in PROOF-HD: antidopaminergic drug use was associated with faster decline, with week-52 differences of 0.66 in cUHDRS and 0.85 in TFC favouring non-users. Confounding cannot be excluded.
Secondary analysisn = 247
Anderson et al. Antidopaminergic Medications and Clinical Outcomes in Huntington Disease: Evidence From the PROOF-HD Placebo-Controlled Trial